Neuropsychiatric complications associated with interferon - alpha -2b treatment of malignant melanoma.

Hdl Handle:
http://hdl.handle.net/10147/94035
Title:
Neuropsychiatric complications associated with interferon - alpha -2b treatment of malignant melanoma.
Authors:
Enudi, W; Udolu, O J
Affiliation:
Adelaide and Meath Hospital, Tallaght, Ireland. waltenudi@yahoo.com
Citation:
Neuropsychiatric complications associated with interferon - alpha -2b treatment of malignant melanoma. 2009, 12 (3):227-8 Afr J Psychiatry (Johannesbg)
Journal:
African journal of psychiatry
Issue Date:
Aug-2009
URI:
http://hdl.handle.net/10147/94035
PubMed ID:
19750253
Abstract:
Several adverse effects have been associated with interferon alpha 2b treatment and neuropsychiatric effects have also been commonly reported. Psychosis and mood disorders have been described in the literature. This case report is of a 30 year old man with malignant melanoma stage 3a who was receiving adjuvant alpha 2b interferon and developed a manic episode two weeks post switching after one month of treatment on a high dose to a low dose. There was no previous psychiatric illness and no known family history of mental illness. This is in keeping with previous reports that mania has been observed in patients undergoing interferon treatment especially after significant dose-reduction or treatment breaks. Mania induced by interferon responds well to antimanic drugs .Since interferon alpha 2b is now commonly used in the treatment of malignant melanoma and other conditions, the need to be aware of its neuropsychiatric complications is essential.
Language:
en
MeSH:
Adult; Antimanic Agents; Antineoplastic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dose-Response Relationship, Drug; Humans; Interferon Alfa-2b; Male; Melanoma; Skin Neoplasms
ISSN:
1994-8220

Full metadata record

DC FieldValue Language
dc.contributor.authorEnudi, Wen
dc.contributor.authorUdolu, O Jen
dc.date.accessioned2010-03-10T10:07:42Z-
dc.date.available2010-03-10T10:07:42Z-
dc.date.issued2009-08-
dc.identifier.citationNeuropsychiatric complications associated with interferon - alpha -2b treatment of malignant melanoma. 2009, 12 (3):227-8 Afr J Psychiatry (Johannesbg)en
dc.identifier.issn1994-8220-
dc.identifier.pmid19750253-
dc.identifier.urihttp://hdl.handle.net/10147/94035-
dc.description.abstractSeveral adverse effects have been associated with interferon alpha 2b treatment and neuropsychiatric effects have also been commonly reported. Psychosis and mood disorders have been described in the literature. This case report is of a 30 year old man with malignant melanoma stage 3a who was receiving adjuvant alpha 2b interferon and developed a manic episode two weeks post switching after one month of treatment on a high dose to a low dose. There was no previous psychiatric illness and no known family history of mental illness. This is in keeping with previous reports that mania has been observed in patients undergoing interferon treatment especially after significant dose-reduction or treatment breaks. Mania induced by interferon responds well to antimanic drugs .Since interferon alpha 2b is now commonly used in the treatment of malignant melanoma and other conditions, the need to be aware of its neuropsychiatric complications is essential.-
dc.language.isoenen
dc.subject.meshAdult-
dc.subject.meshAntimanic Agents-
dc.subject.meshAntineoplastic Agents-
dc.subject.meshAntipsychotic Agents-
dc.subject.meshBenzodiazepines-
dc.subject.meshBipolar Disorder-
dc.subject.meshDose-Response Relationship, Drug-
dc.subject.meshHumans-
dc.subject.meshInterferon Alfa-2b-
dc.subject.meshMale-
dc.subject.meshMelanoma-
dc.subject.meshSkin Neoplasms-
dc.titleNeuropsychiatric complications associated with interferon - alpha -2b treatment of malignant melanoma.en
dc.contributor.departmentAdelaide and Meath Hospital, Tallaght, Ireland. waltenudi@yahoo.comen
dc.identifier.journalAfrican journal of psychiatryen

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.